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E D I T O R I A L
Neuroactive steroids and the new decade
The term ‘neurosteroids’ started to be used in the 1980s to indicate 
a family of steroids synthesised within the brain and regulating, via 
steroid receptors or other receptors, several brain functions. Later 
on, the term ‘neuroactive steroids’ was introduced to include those 
steroids that are not synthesised in the brain or are only partly me-
tabolised (eg, the transformation of testosterone into oestradiol via 
the action of brain aromatase) but can interact with neural circuits. 
During the first two decades of the current century, the number of 
published papers in this field increased by 3620 (source PubMed, 
keywords neurosteroid* or neuroactive steroid*), demonstrating a 
continuous interest in this wide topic. Our international congresses, 
started at the beginning of the century, have covered the entire 
scope of this broad research field, and contributions to these bien-
nial meetings have been published in a series of special issues for 
different journals.1-9
The present special issue includes many of the invited lectures 
presented during the last edition of the “Steroids and Nervous 
System” meeting (Torino, February 2019), contributed as contem-
porary reviews or as original articles. The papers not only embrace 
classical themes such as gonadal steroids and glucocorticoids, but 
also very new topics such as the involvement of neuroactive steroids 
in the control of energy homeostasis and the development of trans-
lational models for a variety of neural diseases in which neuroactive 
steroids are implicated.
The paper by Ball et al10 illustrates the multiple roles of testos-
terone with respect to regulating a highly specialised neural circuit 
(the avian song system) in both males and females. One of the cen-
tral aspects of reproduction, the switch of oestradiol action from 
negative- to positive-feedback in the regulation of the gonadotro-
phin-releasing hormone system, is widely discussed in the paper 
by Moenter et al.11 Rapid, nonclassical effects of oestradiol on the 
basal cholinergic neurones in mice are discussed in the paper by Kim 
et al12, demonstrating the presence of a marked sex difference in 
oestradiol-induced nonclassical effects and the intracellular distri-
bution of oestrogen receptors in cholinergic neurones of the basal 
forebrain.
Glucocorticoids are used clinically during pregnancy to pre-
vent complications (ie, prematurity), with the recreational use of 
cannabis during pregnancy also increasing at the same time; the 
potential implications of co-exposure to these compounds on the 
developing brain and later neurodevelopmental consequences are 
discussed in the review by Franks et al.13 The study by Lesuis et 
al14 demonstrates that both corticosterone and β-adrenergic re-
ceptor activation may cooperate to increase hippocampal spine 
number.
A very promising new field of research is the involvement of neu-
roactive steroids in the control of metabolism. In particular, a review 
by Kammel and Correa15 elucidates the organisation of the hypo-
thalamic ventromedial nucleus (VMH) with a particular emphasis on 
sexual differences involving the presence of phenotypically distinct 
and sexually differentiated neurone populations within the VMH. 
In addition, oestrogenic regulation of glucose-excited neurones, as 
well as how this may affect glucose and energy homeostasis, is dis-
cussed by Hirschberg et al.16 The review by Hidalgo-Lanussa et al17 
discusses the relationships between lipotoxicity (a consequence of 
obesity or of the metabolic syndrome) and the development of neu-
rodegenerative diseases, such as Alzheimer's disease. In this review, 
a cellular and molecular mechanism is proposed to explain the neu-
roprotective effect of oestrogens. Finally, the experimental study 
of Freire-Regatillo et al.18 demonstrates that peripubertal male and 
female mice respond differently to short-term dietary changes in a 
manner different from that reported in adults. This is also interesting 
in view of the effects on metabolism and neuroendocrine circuits 
that some molecules termed metabolic disruptors, including several 
xenoestrogens or xenoandrogens,19,20 may have when exposure oc-
curs in adult life or in early life.
The neuroprotective effects of neuroactive steroids have been 
discussed for a long time, although several promising translational 
models have only become available in recent years. These mod-
els may better elucidate the role of neuroactive steroids in neural 
diseases, and several were presented during the meeting and are 
collected in this special issue. The active form of vitamin D (called 
calcitriol) functions as a steroid hormone acting via both genomic 
and nongenomic pathways. Calcitriol and other vitamin D analogues 
affect steroid hormone synthesis and/or signalling in the nervous 
system, as well as cell proliferation. The review by Norlin21 discusses 
the possible roles of vitamin D analogues as candidates for the fu-
ture improved treatment of human glioma and possibly also other 
cancers of the nervous system.
Oestrogens have several functions in the brain. In particular, 
they may enhance extinction learning across species and are consid-
ered as risk factors that may slow or accelerate natural ageing pro-
cesses in women. In the review by Hammond et al,22 it is suggested 
that these neuroactive steroids may have a role in the treatment of 
post-traumatic stress disorder, particularly in women. The review 
by Miller et al23 indicates that studies on gonadal hormones as risk 
factors in humans require the follow up of diverse cohorts over 
long periods of time, as is currently under way at the Mayo clinic. 
Finally, several brain diseases are linked to alterations in mitochon-
drial function, and gonadal hormones may regulate the metabolism 
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and synthesis of key phospholipids such as cardiolipin. These events 
could be related to the homeostatic and protective actions of ste-
roids in neural cells, as well as to the manifestation of sex differences 
in neurodegenerative disorders.24 The involvement of progesterone 
in neuroprotection and immunomodulation in Parkinson's disease 
is described in a mouse model in the study by Jarras et al.25 Other 
neuroactive steroids are involved in complications of sleep depriva-
tion,26 in the imbalance of inhibitory and excitatory actions during 
pregnancy that program for poor behavioural outcomes in a sex-de-
pendent manner later in life,27 in some psychiatric diseases such as 
Tourette's syndrome,28 and in the regulation of mitochondrial func-
tion in tauopathies.29
Finally, the review by Patisaul30 describes the first results of a 
large project (the FDA collaborative project, CLARITY-BPA) on the 
effects of bisphenol A, an endocrine disruptor acting principally as 
an xenoestrogen that is found in large amounts in the environment. 
In particular, in this review, the results obtained regarding the action 
of bisphenol A on both brain and behaviour are discussed.
In conclusion, the new decade of studies of neuroactive steroids 
will certainly be dedicated to the investigation of their basic prop-
erties and mechanisms of action; however, as seen in this special 
issue, it will also be the time to start clinical trials that aim to explore 
the real neuroprotective properties of these molecules and develop 
even more potent analogues.
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